These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Phagocytosis of breast cancer cells mediated by anti-MUC-1 monoclonal antibody, DF3, and its bispecific antibody. Akewanlop C; Watanabe M; Singh B; Walker M; Kufe DW; Hayes DF Cancer Res; 2001 May; 61(10):4061-5. PubMed ID: 11358826 [TBL] [Abstract][Full Text] [Related]
3. Promoting antibody-dependent cellular phagocytosis for effective macrophage-based cancer immunotherapy. Cao X; Chen J; Li B; Dang J; Zhang W; Zhong X; Wang C; Raoof M; Sun Z; Yu J; Fakih MG; Feng M Sci Adv; 2022 Mar; 8(11):eabl9171. PubMed ID: 35302839 [TBL] [Abstract][Full Text] [Related]
4. Combined strategies for effective cancer immunotherapy with a novel anti-CD47 monoclonal antibody. Ni H; Cao L; Wu Z; Wang L; Zhou S; Guo X; Gao Y; Jing H; Wu M; Liu Y; Ding J; Zhang P; Zhou Y; Chen B; Xiong Y; Sun J; Prinz B; Baruah H; Geoghegan J; Yu M; Wu W; Liu J Cancer Immunol Immunother; 2022 Feb; 71(2):353-363. PubMed ID: 34165607 [TBL] [Abstract][Full Text] [Related]
5. Macrophages are critical effectors of antibody therapies for cancer. Weiskopf K; Weissman IL MAbs; 2015; 7(2):303-10. PubMed ID: 25667985 [TBL] [Abstract][Full Text] [Related]
6. Nanoparticle-Enabled Dual Modulation of Phagocytic Signals to Improve Macrophage-Mediated Cancer Immunotherapy. Zhang YR; Luo JQ; Zhang JY; Miao WM; Wu JS; Huang H; Tong QS; Shen S; Leong KW; Du JZ; Wang J Small; 2020 Nov; 16(46):e2004240. PubMed ID: 33107142 [TBL] [Abstract][Full Text] [Related]
7. Efficient Innate Immune Killing of Cancer Cells Triggered by Cell-Surface Anchoring of Multivalent Antibody-Recruiting Polymers. Uvyn A; De Coen R; Gruijs M; Tuk CW; De Vrieze J; van Egmond M; De Geest BG Angew Chem Int Ed Engl; 2019 Sep; 58(37):12988-12993. PubMed ID: 31206941 [TBL] [Abstract][Full Text] [Related]
8. Targeted Phagocytosis Induction for Cancer Immunotherapy via Bispecific MerTK-Engaging Antibodies. Carrara SC; Bogen JP; Fiebig D; Grzeschik J; Hock B; Kolmar H Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555321 [TBL] [Abstract][Full Text] [Related]
9. Immunostimulant Hydrogel-Guided Tumor Microenvironment Reprogramming to Efficiently Potentiate Macrophage-Mediated Cellular Phagocytosis for Systemic Cancer Immunotherapy. Liang JL; Jin XK; Luo GF; Zhang SM; Huang QX; Lin YT; Deng XC; Wang JW; Chen WH; Zhang XZ ACS Nano; 2023 Sep; 17(17):17217-17232. PubMed ID: 37584451 [TBL] [Abstract][Full Text] [Related]
10. Myeloid cells as effector cells for monoclonal antibody therapy of cancer. Braster R; O'Toole T; van Egmond M Methods; 2014 Jan; 65(1):28-37. PubMed ID: 23811299 [TBL] [Abstract][Full Text] [Related]
11. "Velcro" engineering of high affinity CD47 ectodomain as signal regulatory protein α (SIRPα) antagonists that enhance antibody-dependent cellular phagocytosis. Ho CC; Guo N; Sockolosky JT; Ring AM; Weiskopf K; Özkan E; Mori Y; Weissman IL; Garcia KC J Biol Chem; 2015 May; 290(20):12650-63. PubMed ID: 25837251 [TBL] [Abstract][Full Text] [Related]
12. Engineering nanoparticles-enabled tumor-associated macrophages repolarization and phagocytosis restoration for enhanced cancer immunotherapy. Gong Y; Gao W; Zhang J; Dong X; Zhu D; Ma G J Nanobiotechnology; 2024 Jun; 22(1):341. PubMed ID: 38890636 [TBL] [Abstract][Full Text] [Related]
13. Antibody-Dependent Phagocytosis of Tumor Cells by Macrophages: A Potent Effector Mechanism of Monoclonal Antibody Therapy of Cancer. Gül N; van Egmond M Cancer Res; 2015 Dec; 75(23):5008-13. PubMed ID: 26573795 [TBL] [Abstract][Full Text] [Related]
14. Phagocytosis checkpoints as new targets for cancer immunotherapy. Feng M; Jiang W; Kim BYS; Zhang CC; Fu YX; Weissman IL Nat Rev Cancer; 2019 Oct; 19(10):568-586. PubMed ID: 31462760 [TBL] [Abstract][Full Text] [Related]
15. SIRPα-specific monoclonal antibody enables antibody-dependent phagocytosis of neuroblastoma cells. Bahri M; Kailayangiri S; Vermeulen S; Galopin N; Rossig C; Paris F; Fougeray S; Birklé S Cancer Immunol Immunother; 2022 Jan; 71(1):71-83. PubMed ID: 34023958 [TBL] [Abstract][Full Text] [Related]